Trial Profile
A retrospective study to evaluate safety and efficacy of high dose erlotinib in EGFR-mutant non-small cell lung cancer (NSCLC) patients with refractory leptomeningeal metastases
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2015
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 05 Nov 2015 New trial record